查詢結果分析
相關文獻
- 心房顫動的抗凝治療
- Sudden Cardiac Death Following Verapamil in a Patient with Wolff-Parkinson-White Syndrome and Dilated Cardiomyopathy--A Case Report and Literature Review Based on Emergency Viewpoints
- 心房顫動的最新治療
- Late Development of Persistent Atrial Fibrillation with Loss of AAI Mode Pacemaker Function and Superior Vena Cava Syndrome--Report of a Case of Sick Sinus Syndrome with Such Complications and Review of Literature
- Electrical Remodeling in Atrial Fibrillation
- 非瓣膜性心房顫動的腦中風預防
- 心房顫動病例及用藥討論
- 手術期間的心房顫動
- Time Course of the ST Segment Changes after Electrical Cardioversion of Chronic Atrial Fibrillation
- 心導管治療陣發性心房纖維顫動
頁籤選單縮合
題名 | 心房顫動的抗凝治療=Anticoagulant Therapy in Atrial Fibrillation |
---|---|
作者姓名(中文) | 鄭文涵; 趙子凡; | 書刊名 | 臺灣醫學 |
卷期 | 24:2 2020.03[民109.03] |
頁次 | 頁179-183 |
專輯 | 心房顫動的抗栓治療 |
分類號 | 418.2321 |
關鍵詞 | 心房顫動; 新型口服抗凝劑; Warfarin; Coumadin; Atrial fibrillation; NOACs; |
語文 | 中文(Chinese) |
中文摘要 | 預防中風在心房顫動治療中至關重要。雖然warfarin(Coumadin)可有效降低心房顫動的中風風險達64%,但由於其併發症和局限性,大大降低醫師處方的意願和患者的順從性。因此,warfarin(Coumadin)的使用不足一直是一個全球性的問題。目前已有四種不同於warfarin(Coumadin)的新型口服抗凝劑問世,新型口服抗凝劑在預防缺血性腦中風方面具有與warfarin(Coumadin)同等的功效,並且大幅降低腦出血的風險。在新型口服抗凝劑的時代,醫師能夠更簡易、更安全地處方抗凝劑給需要抗凝治療的心房顫動病患。隨著我們對於新型口服抗凝劑的了解與使用經驗的增加,也為心房顫動患者帶來更好的預後。 |
英文摘要 | Stroke prevention is crucial for the managements of atrial fibrillation (AF). Most thromboembolic events of AF are prominently deferred with oral anticoagulants (OACs). Although warfarin effectively reduces the risk of AF-associated stroke by 64% and all-cause mortality by 26% compared to control/placebo, the underuse of warfarin (Coumadin) remains a worldwide issue due to its complications and limitations, which bothered both physicians and patients. With the introduction of novel oral anticoagulants (NOACs), which are at least as effective as warfarin (Coumadin) for stroke prevention, and are much safer especially with regard to the risk of intra-cranial hemorrhage, more and more AF patients received OACs to prevent stroke. These advances in AF-associated stroke management would positively convert into better outcomes for AF patients, especially as our knowledge and experience with NOACs grow. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。